OCUL
Ocular TherapeutixยทNASDAQ
--
--(--)
--
--(--)
OCUL Profile
Ocular Therapeutix, Inc.
A biopharmaceutical company focused on innovative therapies for diseases and conditions of the eye
15 Crosby Drive, Bedford, MA 01730
--
Ocular Therapeutix, Inc., was established in Delaware on September 12, 2006. The company is an integrated biopharmaceutical company focused on developing treatments for retinal diseases and other eye diseases. Its lead drug candidate, AXPAXLI (OTX-TKI), an investigational axitinib intravitreal hydrogel for wet age-related macular degeneration and diabetic retinal disease, is currently in Phase 3 registration trials. The company also commercializes DEXTENZA, an FDA-approved corticosteroid insert for postoperative inflammation and itching, and advances other drug candidates based on its proprietary ELUTYX bioabsorbable hydrogel technology.
